Journal Reprints: Risk-Mitigating Info Should Be “At Least As Persuasive” As Existing Sources
This article was originally published in The Pink Sheet Daily
FDA quickly drafts guidance in response to stakeholder questions related to distribution of articles on unapproved uses.
You may also be interested in...
FDA has revised, but not loosened, its 2009 final guidance on good reprint practices for distribution of journal articles on unapproved uses of approved drugs and devices.
AstraZeneca will reacquire Allergan's investigational IL-23 inhibitor brazikumab, and Nestle is to buy its GI drug Zenpep, which had nine-month revenue of $208m.
In joint complaint, the FTC and New York Attorney General allege scheme to block generic Daraprim and maintain exorbitant list price; they cite hundreds of emails the incarcerated Shkreli has exchanged with co-defendant in last six months.